References

1. Lentz MR. The role of therapeutic apheresis in the treatment of cancer: a review. Ther Apher 1999;3(1):40-49.
2. Lentz MR. The phylogeny of oncology. Mol Biother 1990;2:137-144.
3. Lentz MR, Hubbard W, Fischer C. Low molecular weight protein apheresis andregression of breast cancer. Jpn J Apheresis 1997;16(1):107-114.
4. Gatanaga T, Lentz MR, Masunaka I et al. Identification of TNF-LT Blocking Factors in the Serum and Ultrafiltrates of Human Cancer Patients. Lymphokine Research 1990; 9 (2): 225-229
5. Gatanaga T, Hwang CD, Kohr W, Lentz, M.R. et al. Purification and characterization of an inhibitor (sTNF-R) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients 1990; Proc Natl Acad Sci USA; 87 (22): 8781 8784
6. Israel L, Edelstein R, Mannoni P et al. Plasmapheresis and immunological control of cancer. Lancet 1976; II: 642-3
7. Lentz MR. Continuous Whole Blood UltraPheresisTM Procedure in Patients with Metastatic Cancer. Journal of Biological Response Modifiers 1989; 8: 511-527
8. Lentz MR, Hubbard W, Fischer C. Low Molecular Weight Protein Apheresis and Regression of Breast Cancer. Jpn J. Apheresis 1997; 16 (1): 107-114
9. Lentz MR. The Role of Therapeutic Apheresis in the Treatment of Cancer: A Review of Therapeutic Apheresis 1999; 3 (1): 40-49
10. Schall TJ, Lewis M, Koller KJ et al. Molecular Cloning and Expression of a Receptor for Human TNF. Cell 1990; 61: 361-371
11. Aderka D, Englemann H, Hornik V et al. Increased Serum Levels of Soluble Receptors for Tumor Necrosis Factor in Cancer Patients. Cancer Res 1991; 51: 5602-5607
12. Selinsky CL, Buroughs KL, Halsey WA et al. Multifaceted inhibition of anti-tumor immune mechanisms by soluble tumor necrosis receptor type I. Immunology 1998; 94: 88 93
13. Langkopf F, Atzpodien J. Soluble TNF-Rs as prognostic factors in cancer patients. Lancet 1994; 344 (8923): 681-682